Sage Therapeutics Soars: Stock Adds 7.1% in Session

Sage Therapeutics, Inc. SAGE was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $83.89 –$156.27 in the past one-month time frame, witnessed a sharp increase on Friday.

The move came after Sage announced favorable results for phase 2 trials of its SAGE-217 treatment for severe major depressive disorder.

The company has seen three negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Sage Therapeutics, Inc. Price and Consensus

Sage Therapeutics, Inc. Price and Consensus | Sage Therapeutics, Inc. Quote

Sage Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

A better-ranked stock in the in the Medical  sector is Collegium Pharmaceutical, Inc. COLL, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is SAGE going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report
 
Collegium Pharmaceutical, Inc. (COLL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research